BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU

被引：0
|
作者：
Moreno, M. [1 ]
Arce, J. [1 ]
Cruz, A. [2 ]
Carpio Farro, R. [3 ]
机构：
[1] Sanofi Aventis Colombia, Bogota, Cun, Colombia
[2] Hosp Alberto Sabogal, Magdalena Del Mar, Peru
[3] Sanofi Aventis Peru, Lima, Peru
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND37
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [21] A retrospective analysis in patients with relapsing-remitting multiple sclerosis
    Maeurer, Mathias
    Lang, Michael
    Elias, Wolfgang
    Ries, Stefan
    Reifschneider, Stefan
    Kaefferlein, Wolfgang
    Windhagen, Susanne
    Wensdoerfer, Colin
    Niemczyk, Gabriele
    Schikhnaier, Petra
    Schwab, Stefan
    [J]. MULTIPLE SCLEROSIS, 2008, 14 : S164 - S165
  • [22] BUDGET IMPACT ANALYSIS OF FINGOLIMOD IN RELAPSING REMITTING MULTIPLE SCLEROSIS
    Ruggeri, M.
    D'Ausilio, A.
    Lo Muto, R.
    Cottone, S.
    Ghezzi, A.
    Mecozzi, A.
    Sacchini, D.
    Mangone, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A393 - A393
  • [23] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Aungsumart, Saharat
    Turongkaravee, Saowalak
    Youngkong, Sitaporn
    Apiwattanakul, Metha
    Thakkinstian, Ammarin
    Chaikledkaew, Usa
    [J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [24] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Saharat Aungsumart
    Saowalak Turongkaravee
    Sitaporn Youngkong
    Metha Apiwattanakul
    Ammarin Thakkinstian
    Usa Chaikledkaew
    [J]. BMC Health Services Research, 23
  • [25] BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Sanchez-de la Rosa, R.
    Sabater, E.
    Casado, M. A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A319 - A319
  • [26] Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis
    Iovino, Aniello
    Aruta, Francesco
    Carotenuto, Antonio
    Manganelli, Fiore
    Iodice, Rosa
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 98 - 100
  • [27] Alemtuzumab and Thyroid Autoimmunity in Relapsing-Remitting Multiple Sclerosis Patients in CAMMS223
    Brinar, Vesna
    [J]. NEUROLOGY, 2011, 76 (09) : A246 - A246
  • [28] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis is independent of baseline status
    Coles, A. J.
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 : 55 - 55
  • [29] Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Zimmermann, J.
    Buhl, T.
    Mueller, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 382 - 382
  • [30] Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated With fingolimod
    Maria Cabrera-Maqueda, Jose
    Fuentes Rumi, Luna
    Valero Lopez, Gabriel
    Alba Isasi, Teresa
    Hernandez-Clares, Rocio
    Carreon Guarnizo, Ester
    Jimenez Veiga, Judith
    Iniesta-Martinez, Francisca
    Leon-Hernandez, Aida
    Zamarro Parra, Joaquin
    Morales Ortiz, Ana
    Meca Lallana, Jose
    [J]. NEUROLOGY, 2019, 92 (15)
12345